셀트리온제약

068760KOSDAQ의약품 제조업

54.3 / 100

Reference Date: 2026-04-13

Financial Score19.5 / 40

News Sentiment18.8 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but PER raises overvaluation concerns. Declined 8.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Celltrion Pharma is a pharmaceutical company with KGMP, U.S. cGMP, and EU-GMP certifications, producing specialty and biopharmaceuticals at facilities in Jincheon and Ochang, South Korea. Key products include the liver disease treatment 'Godeks' and biosimilars such as 'Ramsima', 'Omlizumab', 'Stelizumab', and 'Aducanumab'. Sales in 2024 rose 22.9% year-on-year to 4.778 trillion KRW.

Number of Employees

1,006people

Average Salary

77.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

62.78Industry Average 14.800.0Point

4.2x industry avg (risky)

PBR

5.61Industry Average 1.040.0Point

5.4x industry avg (risky)

ROE

9.31Industry Average 4.427.0Point

2.1x industry avg (excellent)

Debt Ratio

9.14Industry Average 11.984.0Point

In line with industry avg

Trend 2023~20258.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲17.6% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲26.9% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 6.9% (improving, 3yr)

Detailed News Sentiment

8 totalPositive 5Neutral 0Negative 0Average Sentiment Score 90

Positive
셀트리온, 송도에 18만 리터 규모 4·5공장 증설…1조2천억원 투자
셀트리온이 송도에 1.2조원을 투자하여 18만 리터 규모의 4·5공장을 증설하고 미국 공장도 7.5만 리터 증설을 결정하며 총 DS 캐파를 57만 리터로 확장한다.
Positive
셀트리온, 1.2조 투자해 송도내 신규 원료의약품 생산시설 증설
셀트리온이 바이오의약품 수요 대응 및 글로벌 생산 경쟁력 강화를 위해 송도 본사 내 1조원 이상을 투자하여 신규 원료의약품 생산시설을 증설한다.
Positive
'수요 급증 대응' 셀트리온, 송도 4·5공장 증설…1.2조 투입
셀트리온이 글로벌 바이오의약품 수요 급증에 대응하기 위해 송도 4·5공장 동시 증설과 미국 공장 확장을 통해 총 57만 리터 규모의 생산 능력을 확보할 계획이다.

Detailed Momentum

52-week position3.0Point

52w lower range (35%)

Current 56,000Won52-week high 75,70052-week low 45,304

1-month return1.0Point

1m -8.94% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

15 totalPositive 0Neutral 15Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-04-10
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-10
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-03
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-03
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-03